Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

TERN-601

Stage Phase 2Stale

Sponsor Terns, Inc

Class Oral small molecule

Mechanism oral GLP-1 receptor agonist

Sources

registry, as of 2026-08-10Stale

https://clinicaltrials.gov/study/NCT06854952

A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Enrollment 167. Conditions Overweight or Obesity. This is a Phase 2a multicenter, randomized, double-blind, placebo-controlled clinical trial studying the efficacy, safety, and tolerability of orally administered TERN-601 in adults with overweight or obesity. deaths TERN-601 250 mg 0 nausea TERN-601 250 mg 16 vomiting TERN-601 250 mg 2 diarrhoea TERN-601 250 mg 4 deaths TERN-601 500 mg (Slow Titration) 0 nausea TERN-601 500 mg (Slow Titration) 17 vomiting TERN-601 500 mg (Slow Titration) 10 diarrhoea TERN-601 500 mg (Slow Titration) 4 deaths TERN-601 500 mg 0 nausea TERN-601 500 mg 22 vomiting TERN-601 500 mg 13 diarrhoea TERN-601 500 mg 4

ClinicalTrials.gov NCT06854952 protocol and results modules

publication, as of 2026-08-26Stale

https://pubmed.ncbi.nlm.nih.gov/42528333/

Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies. The safety, tolerability, pharmacokinetics, and efficacy of TERN-601, a onc

PMID 42528333

Studies

FALCON

Registry NCT06854952

Phase Phase 2

Status Completed

Enrollment 167

Start 2025-03-07

Primary completion 2025-08-19

Study completion 2025-09-19

Catalyst Primary completion. 2025-08-19. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

TERN-601 250 mg

Dose 250 mg

Regimen once daily

Comparator placebo

Population Overweight or Obesity

deaths

participants with nausea, 16 participantsStale

participants with vomiting, 2 participantsStale

participants with diarrhoea, 4 participantsStale

TERN-601 500 mg (slow titration)

Dose 500 mg

Regimen once daily

Comparator placebo

Population Overweight or Obesity

deaths

participants with nausea, 17 participantsStale

participants with vomiting, 10 participantsStale

participants with diarrhoea, 4 participantsStale

TERN-601 500 mg

Dose 500 mg

Regimen once daily

Comparator placebo

Population Overweight or Obesity

TERN-601 750 mg

Dose 750 mg

Regimen once daily

Comparator placebo

Population Overweight or Obesity

deaths

participants with nausea, 20 participantsStale

participants with vomiting, 11 participantsStale

participants with diarrhoea, 1 participantsStale

Matching Placebo

Regimen once daily

Population Overweight or Obesity

deaths

participants with nausea, 3 participantsStale

participants with vomiting, 0 participantsStale

participants with diarrhoea, 2 participantsStale